The United Kingdom and the United States have hammered out a key bilateral deal that will keep no tariffs on British medicine shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to boost funding on medicines through the National Health Service (NHS). This commitment guarantees that tariffs on these key goods will stay at nothing for a duration of the next three years.
This agreement comes after recent threats to hike tariffs on patented drug imports, with potential rates floated up to 100%.
"This arrangement between the Britain bolsters the global environment for new treatments and introduces much-needed balance to transatlantic medicine commerce," an announcement said.
Economic Impact
Medicines constitute one of the Britain's largest exports to the US, which is by far the primary buyer for major UK drugmakers.
Statistics reveal that in the 12 months leading up to last September, the UK shipped medicines totaling £11.1bn to the US. This figure made up 17.4% of all goods exports in that span.
"This guarantee protects employment, stimulates investment and facilitates the UK to emerge as a global hub for medical research," a minister commented.
Specific British Pledges
The deal includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total NHS spending on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must pay back to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%.
Industry Background
This agreement comes amid a protracted dispute between the sector and the ministers over drug pricing and regulatory access.
The disagreement were exacerbated by claims that US customers were charged significantly more for the same drugs than people in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its total funding over the last ten years.
